Geneva – a country with record numbers now monitoring and reporting on antibiotic resistance – is a major step in the global fight against drug resistance. But the data they provide suggest that an alarming number of bacterial infections are increasingly resistant to drugs for their treatment.
Director General of the World Health Organization (WHO), Dr. Tedros Adnom Ghebius said, "As we gather more evidence, we see more clearly and more worryingly how we are losing important antimicrobial drugs around the world." "These data underscore the importance of both protecting the antimicrobials we have and developing new ones, treating infections, preserving the health benefits made in the last century, and ensuring a secure future."
Since WHO's Global Antimicrobial Resistance and Utilization Monitoring System (GLASS) report in 2018, participation has grown rapidly. In just three years of existence, the system now collects data from over 64 000 surveillance sites, with more than 2 million patients enrolled from 66 countries around the world. In 2018, there were 729 surveillance sites in 22 countries.
More countries are also reporting on recently approved indicators on antimicrobial resistance (AMR) as part of the Sustainable Development Goals Monitoring. "The vast expansion of countries, facilities and patients covered by the new AMR surveillance system allows us to better document the emerging public health threat of AMR," said Assistant Director General for Antimicrobial Resistance at WHO.
High rates of resistance among antimicrobials are often used to treat common infections, such as urinary tract infections or some form of diarrhea, indicating that the world is running out of effective ways to combat these diseases. . For example, the rate of resistance to ciprofloxacin, an antimicrobial often used to treat urinary tract infections, varies from 8.4% to 92.9% in 33 reporting countries.
The WHO is concerned that improper use of antibiotics during the COVID-19 epidemic will further fuel this trend. Evidence suggests that only a small proportion of COVID-19 patients require antibiotics for the subsequent treatment of bacterial infection and that the organization provided antibiotic therapy or prophylaxis to patients with mild COVID-19 Has not provided guidance for patients with or suspected COVID-19 disease. Unless there is a clinical indication to do so.
Dr. Balakhi, said: "We believe this clear guidance on the use of antibiotics in the COVID-19 pandemic allows both countries to deal with COVID-19 effectively and prevent the emergence and transmission of antimicrobial resistance (AMR) in the pandemic context." Will help. "
WHO remains concerned with a decline in investment (involving the private sector) and a lack of innovation in the development of new antimicrobial treatments – factors that are reducing efforts to combat drug-resistant infections.
He said, "We should increase global cooperation and partnership between the public and private sectors, to provide financial and non-financial incentives for the development of new and new antimicrobials."
To support this effort, WHO has documented two products on target product profiles for the development of new treatments for common resistant bacterial infections and potential return on investment of antibacterial drug development, economic models simulating risks and potential returns. Issued.